Von Eschenbach to resign from National Cancer Institute post

FDA acting commissioner Andrew von Eschenbach said this week he would resign from his other job, as director of the National Cancer Institute (NCI), effective June 10. Von Eschenbach’s holding of both positions had raised questions of a potential conflict of interest. He has led NCI since 2002. Von Eschenbach became acting commissioner in September 2005 and in March was nominated by President Bush to lead the regulatory agency. His confirmation remains “in limbo” amid debate on the FDA’s position on the OTC status of Barr’s emergency contraceptive pill Plan B.
You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.